These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 28196874)

  • 1. Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell Carcinoma.
    Narayan V; Keefe S; Haas N; Wang L; Puzanov I; Putt M; Catino A; Fang J; Agarwal N; Hyman D; Smith AM; Finkelman BS; Narayan HK; Ewer S; ElAmm C; Lenihan D; Ky B
    Clin Cancer Res; 2017 Jul; 23(14):3601-3609. PubMed ID: 28196874
    [No Abstract]   [Full Text] [Related]  

  • 2. Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.
    Iacovelli R; Ciccarese C; Fornarini G; Massari F; Bimbatti D; Mosillo C; Rebuzzi SE; Di Nunno V; Grassi M; Fantinel E; Ardizzoni A; Tortora G
    Br J Clin Pharmacol; 2019 Jun; 85(6):1283-1289. PubMed ID: 30740760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate.
    Telli ML; Witteles RM; Fisher GA; Srinivas S
    Ann Oncol; 2008 Sep; 19(9):1613-8. PubMed ID: 18436521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of brain natriuretic peptide after acute myocardial infarction.
    Güneş Y; Okçün B; Kavlak E; Erbaş C; Karcier S
    Anadolu Kardiyol Derg; 2008 Jun; 8(3):182-7. PubMed ID: 18524723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
    Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
    Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: a multicenter analysis.
    Di Lorenzo G; Autorino R; Bruni G; Cartenì G; Ricevuto E; Tudini M; Ficorella C; Romano C; Aieta M; Giordano A; Giuliano M; Gonnella A; De Nunzio C; Rizzo M; Montesarchio V; Ewer M; De Placido S
    Ann Oncol; 2009 Sep; 20(9):1535-1542. PubMed ID: 19474115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Longitudinal Assessment of Vascular Function With Sunitinib in Patients With Metastatic Renal Cell Carcinoma.
    Catino AB; Hubbard RA; Chirinos JA; Townsend R; Keefe S; Haas NB; Puzanov I; Fang JC; Agarwal N; Hyman D; Smith AM; Gordon M; Plappert T; Englefield V; Narayan V; Ewer S; ElAmm C; Lenihan D; Ky B
    Circ Heart Fail; 2018 Mar; 11(3):e004408. PubMed ID: 29664405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The utility of cardiac biomarkers and echocardiography for the early detection of bevacizumab- and sunitinib-mediated cardiotoxicity.
    Bordun KA; Premecz S; daSilva M; Mandal S; Goyal V; Glavinovic T; Cheung M; Cheung D; White CW; Chaudhary R; Freed DH; Villarraga HR; Herrmann J; Kohli M; Ravandi A; Thliveris J; Pitz M; Singal PK; Mulvagh S; Jassal DS
    Am J Physiol Heart Circ Physiol; 2015 Aug; 309(4):H692-701. PubMed ID: 26092985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma N-terminal pro-brain natriuretic peptide as prognostic marker in fatal cardial decompensation with sunitinib malate therapy.
    Staehler M; Haseke N; Zilinberg K; Stadler T; Stief CG
    Urol Int; 2010; 84(1):119-21. PubMed ID: 20173383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
    Schmidinger M; Zielinski CC; Vogl UM; Bojic A; Bojic M; Schukro C; Ruhsam M; Hejna M; Schmidinger H
    J Clin Oncol; 2008 Nov; 26(32):5204-12. PubMed ID: 18838713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
    Wong MK; Jarkowski A
    Pharmacotherapy; 2009 Apr; 29(4):473-8. PubMed ID: 19323623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F; Barac A; Tan MT; Asch FM; Smith KL; Dang C; Isaacs C; Swain SM
    Oncologist; 2017 May; 22(5):518-525. PubMed ID: 28314836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiotoxicity due to Chemotherapy: the Role of Biomarkers.
    Stevens PL; Lenihan DJ
    Curr Cardiol Rep; 2015 Jul; 17(7):603. PubMed ID: 26026994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
    Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
    J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature.
    Gallucci G; Tartarone A; Tocchetti CG; Bochicchio AM; Coccaro M; Capobianco A; Maurea N; Improta G; Zupa A; Aieta M
    Future Oncol; 2013 Jan; 9(1):127-33. PubMed ID: 23252570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of continuous once-daily dosing of sunitinib as first-line treatment in patients with metastatic renal cell carcinoma.
    Barrios CH; Hernandez-Barajas D; Brown MP; Lee SH; Fein L; Liu JH; Hariharan S; Martell BA; Yuan J; Bello A; Wang Z; Mundayat R; Rha SY
    Cancer; 2012 Mar; 118(5):1252-9. PubMed ID: 21898376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echocardiographic Assessment for the Detection of Cardiotoxicity Due to Vascular Endothelial Growth Factor Inhibitor Therapy in Metastatic Renal Cell and Colorectal Cancers.
    Nhola LF; Abdelmoneim SS; Villarraga HR; Kohli M; Grothey A; Bordun KA; Cheung M; Best R; Cheung D; Huang R; Barros-Gomes S; Pitz M; Singal PK; Jassal DS; Mulvagh SL
    J Am Soc Echocardiogr; 2019 Feb; 32(2):267-276. PubMed ID: 30459123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
    Chu TF; Rupnick MA; Kerkela R; Dallabrida SM; Zurakowski D; Nguyen L; Woulfe K; Pravda E; Cassiola F; Desai J; George S; Morgan JA; Harris DM; Ismail NS; Chen JH; Schoen FJ; Van den Abbeele AD; Demetri GD; Force T; Chen MH
    Lancet; 2007 Dec; 370(9604):2011-9. PubMed ID: 18083403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib.
    Daste A; Laine M; Gross-Goupil M; Bernhard JC; François L; Ravaud A
    Future Oncol; 2017 Jun; 13(14):1219-1221. PubMed ID: 28606002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.